MCID: UVT001
MIFTS: 62

Uveitis

Categories: Eye diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Uveitis

MalaCards integrated aliases for Uveitis:

Name: Uveitis 12 77 30 56 45 15 41 17 74

Classifications:



External Ids:

Disease Ontology 12 DOID:13141
MeSH 45 D014605
NCIt 51 C26909
SNOMED-CT 69 75614007
ICD10 34 H20.9
UMLS 74 C0042164

Summaries for Uveitis

Disease Ontology : 12 A uveal disease is characterized by inflammation of any of the layers of the uvea of the eye, which includes the iris, ciliary body, and choroid.

MalaCards based summary : Uveitis is related to fuchs' heterochromic uveitis and posterior uveitis. An important gene associated with Uveitis is NOD2 (Nucleotide Binding Oligomerization Domain Containing 2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Fluocinolone Acetonide and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include eye, t cells and endothelial, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 77 Uveitis is the inflammation of the uvea, the pigmented layer that lies between the inner retina and the... more...

Related Diseases for Uveitis

Diseases in the Uveitis family:

Autoimmune Uveitis Posterior Uveitis
Intermediate Uveitis Infectious Anterior Uveitis
Anterior Uveitis Infectious Posterior Uveitis

Diseases related to Uveitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 655)
# Related Disease Score Top Affiliating Genes
1 fuchs' heterochromic uveitis 34.1 IL2RA TGFB2
2 posterior uveitis 34.0 CAPN5 IFNG IL2RA RBP3 SAG TNF
3 intermediate uveitis 33.8 CXCR3 HLA-B IFNG IL10 IL2RA TNF
4 anterior uveitis 33.3 CCL2 CTLA4 HLA-B IL2RA
5 panuveitis 32.8 HLA-B IL10 IL17A RBP3 SAG TNF
6 multifocal choroiditis 32.7 IL10 TNF
7 vitreoretinopathy, neovascular inflammatory 32.5 CAPN5 CCL2 TGFB2
8 vogt-koyanagi-harada disease 32.1 HLA-B IL10 IL17A IL2RA
9 autoimmune uveitis 31.8 CAPN5 CCL2 ICAM1 IFNG IL10 IL17A
10 juvenile rheumatoid arthritis 31.3 IL1R1 IL2RA TNF
11 tropical spastic paraparesis 31.2 CXCR3 HLA-B IFNG IL10 IL17A IL2RA
12 spondyloarthropathy 1 31.0 HLA-B IL17A NOD2 TNF
13 macular retinal edema 31.0 CAPN5 CCL2 ICAM1
14 spondylitis 31.0 HLA-B IL17A NOD2 TNF
15 arthritis 30.8 CCL2 IFNG IL10 IL17A IL1A NOD2
16 scleritis 30.7 IFNG IL4 TNF
17 cytomegalovirus retinitis 30.6 HLA-B IFNG TNF
18 kawasaki disease 30.5 CCL2 IL10 TNF
19 sarcoidosis 1 30.4 CXCR3 IFNG IL2RA NOD2 TNF
20 neuritis 30.4 CCL2 IFNG IL4 TNF
21 mumps 30.4 IFNG IL2RA TNF
22 vasculitis 30.4 CCL2 HLA-B ICAM1 IFNA2 TNF
23 conjunctivitis 30.3 ICAM1 IFNG IL4
24 leptospirosis 30.3 CCL2 IFNG IL10 TNF
25 human immunodeficiency virus infectious disease 30.3 IFNG IL10 TNF
26 oligoarticular juvenile idiopathic arthritis 30.3 CXCR3 IL2RA TNF
27 rubella 30.2 HLA-B IL10 IL4 TNF
28 herpes zoster 30.2 HLA-B IFNA2 IFNG IL10
29 drug reaction with eosinophilia and systemic symptoms 30.2 HLA-B TNF
30 spotted fever 30.2 IFNG IL10 TNF
31 extrapulmonary tuberculosis 30.1 CCL2 IFNG IL10
32 behcet syndrome 30.1 CTLA4 HLA-B IFNA2 IFNG IL10 IL17A
33 meningitis 30.1 CCL2 IFNG IL10 TNF
34 psoriatic arthritis 30.1 HLA-B IL17A IL1A NOD2 TNF
35 toxoplasmosis 30.1 IFNG IL10 IL4 TNF
36 reactive arthritis 30.0 HLA-B IFNG IL10 IL17A TNF
37 herpes simplex virus keratitis 30.0 CCL2 ICAM1
38 stromal keratitis 30.0 CCL2 IL17A IL2RA TNF
39 hepatitis a 29.9 IFNG IL10 TNF
40 temporal arteritis 29.9 CCL2 IFNG TNF
41 joint disorders 29.9 IL17A IL1R1 TNF
42 connective tissue disease 29.9 IFNG IL10 IL1A TNF
43 cytomegalovirus infection 29.9 CCL2 HLA-B TNF
44 ulcerative colitis 29.9 IFNG IL10 IL17A NOD2 TNF
45 pertussis 29.9 IL10 IL1A TNF
46 atherosclerosis susceptibility 29.8 CCL2 ICAM1 TNF
47 allergic conjunctivitis 29.8 ICAM1 IFNG IL4
48 spondyloarthropathy 29.8 HLA-B IFNG IL10 IL17A IL4 TNF
49 keratoconjunctivitis 29.8 ICAM1 IFNG IL4 TNF
50 pyoderma gangrenosum 29.8 IFNA2 NOD2 TNF

Graphical network of the top 20 diseases related to Uveitis:



Diseases related to Uveitis

Symptoms & Phenotypes for Uveitis

GenomeRNAi Phenotypes related to Uveitis according to GeneCards Suite gene sharing:

27 (show all 42)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.34 IL10
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.34 IFNA2
3 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.34 IL10
4 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.34 IL1R1 IL2RA
5 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.34 IL1R1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.34 IL2RA
7 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.34 IL1R1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-124 10.34 IL1R1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-125 10.34 IL10
10 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10.34 IFNA2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-128 10.34 IL10
12 Increased shRNA abundance (Z-score > 2) GR00366-A-130 10.34 IL2RA
13 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.34 IL10
14 Increased shRNA abundance (Z-score > 2) GR00366-A-138 10.34 IL2RA
15 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.34 IL10
16 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.34 IL10
17 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.34 IFNA2 IL1R1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.34 IL2RA
19 Increased shRNA abundance (Z-score > 2) GR00366-A-174 10.34 IL2RA
20 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.34 IFNA2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-183 10.34 IL1R1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-185 10.34 IL2RA
23 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.34 IL2RA
24 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.34 IL10 IL1R1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-2 10.34 IL2RA
26 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.34 IL2RA
27 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.34 IL10
28 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.34 IL10
29 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.34 IFNA2 IL10 IL1R1 IL2RA
30 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.34 IFNA2
31 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.34 IL2RA
32 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.34 IL2RA
33 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.34 IL10 IL2RA
34 Increased shRNA abundance (Z-score > 2) GR00366-A-65 10.34 IL10
35 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.34 IL10 IL2RA
36 Increased shRNA abundance (Z-score > 2) GR00366-A-80 10.34 IL10
37 Increased shRNA abundance (Z-score > 2) GR00366-A-82 10.34 IL10
38 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.34 IL10
39 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.34 IL1R1 IL2RA
40 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.34 IL1R1
41 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 ICAM1 IL10 IL17A IL1A IL2RA NOD2
42 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 ICAM1 IL10 IL17A IL1A IL2RA NOD2

MGI Mouse Phenotypes related to Uveitis:

47 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.31 CTLA4 CXCR3 ICAM1 IFNG IL10 IL17A
2 immune system MP:0005387 10.31 CAPN5 CCL2 CTLA4 CXCR3 ICAM1 IFNG
3 hematopoietic system MP:0005397 10.3 CTLA4 CXCR3 ICAM1 IFNG IL10 IL17A
4 growth/size/body region MP:0005378 10.26 CAPN5 ICAM1 IFNG IL10 IL17A IL1R1
5 digestive/alimentary MP:0005381 10.21 CTLA4 ICAM1 IFNG IL10 IL17A IL2RA
6 endocrine/exocrine gland MP:0005379 10.19 CTLA4 ICAM1 IFNG IL10 IL17A IL1R1
7 mortality/aging MP:0010768 10.17 CAPN5 CTLA4 CXCR3 ICAM1 IFNG IL10
8 craniofacial MP:0005382 10.07 IFNG IL10 IL17A IL1R1 IL4 TGFB2
9 integument MP:0010771 9.97 CTLA4 ICAM1 IFNG IL10 IL1A IL1R1
10 respiratory system MP:0005388 9.85 CTLA4 CXCR3 IFNG IL10 IL17A IL1R1
11 neoplasm MP:0002006 9.8 CXCR3 ICAM1 IFNG IL10 IL1A IL1R1
12 skeleton MP:0005390 9.61 CTLA4 IFNG IL10 IL17A IL1R1 IL4
13 vision/eye MP:0005391 9.32 ICAM1 IFNG IL10 IL1R1 IL2RA IL4

Drugs & Therapeutics for Uveitis

Drugs for Uveitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 305)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 67-73-2 6215
2
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-02-2 5743
3
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 124-94-7 31307
4
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1177-87-3
5
Tobramycin Approved, Investigational Phase 4 32986-56-4 5496 36294
6
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
7
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
8
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
9
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
10
Ranibizumab Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 347396-82-1 459903
11
Infliximab Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 170277-31-3
12
Azathioprine Approved Phase 4,Phase 3,Phase 2,Not Applicable 446-86-6 2265
13
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable 24280-93-1 446541
14
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
15
Diclofenac Approved, Vet_approved Phase 4,Phase 1,Not Applicable 15307-86-5 3033
16
Heparin Approved, Investigational Phase 4,Phase 2 9005-49-6 772 46507594
17
Adalimumab Approved Phase 4,Phase 2,Phase 3,Phase 1 331731-18-1 16219006
18
Ganciclovir Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 82410-32-0 3454
19
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
20
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2 6055-19-2, 50-18-0 2907
21
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2 104987-11-3 445643 439492 6473866
22
Chlorambucil Approved Phase 4 305-03-3 2708
23
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 53-03-2 5865
24
Travoprost Approved Phase 4 157283-68-6 5282226
25
Latanoprost Approved, Investigational Phase 4,Phase 1,Not Applicable 130209-82-4 5311221 5282380
26
Bimatoprost Approved, Investigational Phase 4,Phase 3 155206-00-1 5311027
27
Timolol Approved Phase 4,Phase 3 26839-75-8 33624 5478
28
Apraclonidine Approved Phase 4,Not Applicable 66711-21-5 2216
29
Ketorolac Approved Phase 4,Phase 1 66635-83-4, 74103-06-3 3826
30
Dinoprost Approved, Investigational Phase 4 551-11-1 5283078
31
Dinoprost tromethamine Approved, Vet_approved Phase 4 38562-01-5 5282415
32
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
33
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
34
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
35
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
36
Polyestradiol phosphate Approved Phase 4 28014-46-2
37
Fluprednisolone Approved Phase 4,Phase 3,Phase 2 53-34-9
38
Difluprednate Approved Phase 4,Phase 3,Phase 2 23674-86-4 443936
39
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
40
Certolizumab pegol Approved Phase 4,Phase 3 428863-50-7
41
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
42
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 5538 444795
43
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2920-86-7
44
SB-649868 Experimental, Investigational Phase 4 110-16-7, 110-17-8 444972
45
Lactitol Investigational Phase 4,Not Applicable 585-86-4, 585-88-6 493591
46 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
47 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 481)
# Name Status NCT ID Phase Drugs
1 Flucinolone Acetonide Implant for Treating Refractory Ocular Behcet's Disease Unknown status NCT00720928 Phase 4 flucinolone acetonide
2 Efficacy Comparison Study of Steroids to Control Post-operative Inflammation Unknown status NCT01801774 Phase 4 Subtenon 20-mg triamcinolone injection;Placebo
3 The Efficacy of Methylprednisolone in the Treatment of Patients With Ocular Involvement in Behcet's Disease Unknown status NCT01306955 Phase 4 methylorednisolone
4 Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion Unknown status NCT01827722 Phase 4 Ozurdex;Ranibizumab;Combination Ozurdex with Ranibizumab PRN
5 Effects of Ranibizumab to Delay or Regression Non-proliferative Diabetic Retinopathy(NPDR) With DME Assessed by Microaneurysm Changes: A Pilot Study Unknown status NCT02834663 Phase 4 Lucentis
6 Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients Completed NCT02764697 Phase 4 H.P. ACTHAR SUBCUTANEOUS GEL INJECTION
7 Multi Center Prospective Registry of Infliximab Use for Childhood Uveitis Completed NCT00589628 Phase 4 infliximab;infliximab
8 Multicenter Uveitis Steroid Treatment (MUST) Trial Completed NCT00132691 Phase 4 fluocinolone acetonide intraocular implant;oral corticosteroid with immunosuppressive agents as needed
9 Re-implantation of a Fluocinolone Acetonide Implant for Non-infectious Uveitis Affecting the Posterior Segment Completed NCT00543296 Phase 4 0.59 mg Fluocinolone Acetonide implant
10 TAHOE: Intravitreal Dexamethasone Implant (Ozurdex) for Uveitic Macular Edema Completed NCT01870440 Phase 4 Ozurdex Intravitreal Injection (0.7 mg)
11 The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012) Completed NCT01668004 Phase 4
12 A Study to Compare Ocular Safety and Tolerability of Eye Drops Containing Prednisolone Acetate in Patients With Intraocular Inflammation After Cataract Surgery Completed NCT00170729 Phase 4 Prednisolone acetate
13 Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With POAG Completed NCT01978015 Phase 4 travoprost and timolol maleate fixed combination;latanoprost and maleate timolol fixed combination;bimatoprost and timolol maleate fixed combination;dextran and hypromellose
14 Micropulse Laser Trabeculoplasty (MLT) Versus Selective Laser Trabeculoplasty (SLT) for Treatment of Open Angle Glaucoma Completed NCT01956942 Phase 4
15 Steroids After Laser Trabeculoplasty for Glaucoma Completed NCT00981435 Phase 4 Prednisolone 1%;Ketorolac;Artificial Tears
16 The Effects of BAK on the Blood Aqueous Barrier of Pseudophakic Patients Completed NCT01280110 Phase 4 Hydroxypropylmethylcellulose;Carboxymethylcellulose
17 Evaluation of Dosing Interval of Higher Doses of Ranibizumab Completed NCT00533520 Phase 4 ranibizumab
18 Aqueous Flare of a Hydrophobic Acrylic Single-piece Open-loop IOL With Modified Material Surface Properties Completed NCT01767012 Phase 4
19 Infliximab for the Prevention of Recurrent Crohn's Disease After Surgery Completed NCT00688636 Phase 4 infliximab;placebo
20 Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study) Completed NCT02059655 Phase 4 Bimatoprost;Eye drop solution
21 A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking an Intense Treatment Approach Versus Routine Treatment Completed NCT02897115 Phase 4
22 Intravitreal Aflibercept Injection for the Treatment of Submacular Vascularized Pigment Epithelial Detachment Completed NCT01722656 Phase 4 Aflibercept
23 Saline vs. Lactated Ringers for Emergency Department IV Fluid Resuscitation Completed NCT03133767 Phase 4 Lactated Ringer Solution;Normal Saline 0.9% Infusion Solution Bag
24 A Two Chemoprophylaxis Approaches After Phacoemulsification Surgery Completed NCT03634852 Phase 4 Moxifloxacin hydrochloride 0.5% eye drops;Dexamethasone 0.1% eye drops;Intracameral Moxifloxacin 0.1%;Subconjunctival Triamcinolone acetonide 4 mg /0.4 ml
25 Study of the Effectiveness of Ozurdex for the Control of Uveitis Recruiting NCT02049476 Phase 4 Dexamethasone pellet
26 Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis Recruiting NCT02943057 Phase 4 2% guttae ganciclovir
27 Efficacy and Safety of H.P. Acthar® Gel in Subjects With Severe Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis NIPPU Recruiting NCT03656692 Phase 4 Acthar
28 Macular Edema Nepafenac vs. Difluprednate Uveitis Trial Recruiting NCT01939691 Phase 4 Difluprednate;Nepafenac;Prednisolone acetate
29 A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU Active, not recruiting NCT03020992 Phase 4 Certolizumab Pegol
30 Efficacy and Safety of H.P. ACTHAR GEL in Adults With Retinal Vasculitis Active, not recruiting NCT03066869 Phase 4 H.P. ACTHAR GEL
31 Effect of Intracameral Dexamethasone After Phacoemulsification in Diabetics on Corneal Endothelial Cell Density Not yet recruiting NCT03361709 Phase 4 Dexamethasone;Saline Solutions, Intraocular
32 Open Label Study of Acthar SQ Gel Injection in Patients With Active Anterior Uveitis Terminated NCT02769702 Phase 4 Acthar
33 Use of Thalidomide in Chronic Uveitis Terminated NCT00314665 Phase 4 Thalidomide
34 Efficacy Study of Methotrexate to Treat Sarcoid-associated Uveitis Terminated NCT00918554 Phase 4 Methotrexate;Placebo
35 Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema Terminated NCT02684084 Phase 4 Ozurdex;Lucentis
36 Posterior Subtenon Versus Intravitreal Injection of Triamcinolone Acetonide for Treatment of Uveitic Cystoid Macular Edema Withdrawn NCT02598869 Phase 4 Triamcinolone Acetonide
37 Methotrexate in the Treatment of Axial Spondyloarthritis Withdrawn NCT00298012 Phase 4 Methotrexate
38 Adalimumab in Uveitis Refractory to Conventional Therapy (ADUR Trial) Unknown status NCT00348153 Phase 2, Phase 3 Adalimumab
39 The Safety and Efficacy of a Tumor Necrosis Factor Receptor Fusion Protein on Uveitis Associated With Juvenile Rheumatoid Arthritis Unknown status NCT00012506 Phase 3 TNFR:Fc
40 Loteprednol vs Prednisolone for the Treatment of Intraocular Inflammation Following Cataract Surgery in Children. Unknown status NCT01475643 Phase 3 Loteprednol etabonate;Prednisolones acetate
41 Collaborative Ocular Melanoma Study (COMS) Unknown status NCT00000124 Phase 3
42 Topical Dexamethasone - Cyclodextrin Microparticle Eye Drops for Diabetic Macular Edema Unknown status NCT01523314 Phase 2, Phase 3 dexamethasone - Cyclodextrin eye drops
43 Evaluation of Seelens AF, an Aspheric Intra-Ocular Lens Unknown status NCT00825747 Phase 3
44 To Compare Intravitreal Clindamycin & Dexamethasone With Classic Treatment of Toxoplasmic Retinochoroiditis Unknown status NCT00372294 Phase 3 pyrimethamine-sulfadiazine + prednisolone;Clindamycin+Dexamethasone
45 A Study of Strontium90 Beta Radiation With Lucentis to Treat Age-Related Macular Degeneration Unknown status NCT00454389 Phase 3 ranibizumab
46 A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis Completed NCT01148225 Phase 3 adalimumab
47 Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis Completed NCT01124838 Phase 3 Adalimumab;Prednisone;Placebo
48 Effect of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis Completed NCT01385826 Phase 2, Phase 3 Anti-tumor necrosis factor alpha monoclonal antibody;placebo
49 Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis Completed NCT02517619 Phase 3 Dexamethasone Phosphate Ophthalmic Solution;Prednisolone Acetate Ophthalmic (1%)
50 First-line Antimetabolites as Steroid-sparing Treatment Uveitis Pilot Trial Completed NCT01232920 Phase 3 Methotrexate;Mycophenolate mofetil

Search NIH Clinical Center for Uveitis

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: uveitis

Genetic Tests for Uveitis

Genetic tests related to Uveitis:

# Genetic test Affiliating Genes
1 Uveitis 30

Anatomical Context for Uveitis

MalaCards organs/tissues related to Uveitis:

42
Eye, T Cells, Endothelial, Retina, Testes, Skin, Neutrophil

Publications for Uveitis

Articles related to Uveitis:

(show top 50) (show all 4711)
# Title Authors Year
1
Aqueous Humor Analysis Identifies Higher Branched Chain Amino Acid Metabolism as a Marker for Human Leukocyte Antigen-B27 Acute Anterior Uveitis and Disease Activity. ( 30312576 )
2019
2
Aqueous tap and rapid diagnosis of cytomegalovirus anterior uveitis: the Reggio Emilia experience. ( 30392022 )
2019
3
PD-1 Polymorphisms Are Associated with Susceptibility of Acute Anterior Uveitis in Chinese Population. ( 30540488 )
2019
4
Acute anterior uveitis in spondyloarthritis: a monocentric study of 301 patients. ( 30620268 )
2019
5
BISPHOSPHONATE-INDUCED BILATERAL ANTERIOR UVEITIS AND CHOROIDAL EFFUSIONS WITH SECONDARY ANGLE CLOSURE. ( 30640817 )
2019
6
Chronic Anterior Uveitis in a Patient with CREST Syndrome. ( 30691950 )
2019
7
Inhibitory role of transforming growth factor β2 in experimental autoimmune anterior uveitis. ( 30719689 )
2019
8
Efficacy of anti-tumour necrosis factor-α monoclonal antibodies in patients with non-infectious anterior uveitis. ( 30719968 )
2019
9
Emerging Viral Infections Causing Anterior Uveitis. ( 30794475 )
2019
10
Risk factors associated with persistent anterior uveitis after cataract surgery. ( 30794788 )
2019
11
Preventive effects of tyrosol, a natural phenolic compound, on anterior uveitis induced by anterior chamber paracentesis in healthy beagle dogs. ( 30799325 )
2019
12
Evaluation of choroidal parameters in eyes at the first onset of acute anterior uveitis. ( 30819128 )
2019
13
Novel gene targets for miRNA146a and miRNA155 in anterior uveitis. ( 30297336 )
2019
14
Predicting uveitis in juvenile idiopathic arthritis: from biomarkers to clinical practice. ( 30874452 )
2019
15
Transcriptomic and proteomic analysis of iris tissue and aqueous humor in juvenile idiopathic arthritis-associated uveitis. ( 30885419 )
2019
16
Therapeutic advances in juvenile idiopathic arthritis - associated uveitis. ( 30844943 )
2019
17
Drug Costs, Effectiveness, and Kids in the Crossfire: Adalimumab in Juvenile Idiopathic Arthritis-Associated Uveitis. ( 30803516 )
2019
18
Re: Hughes et al.: Cost-effectiveness analysis of adalimumab for the treatment of uveitis associated with juvenile idiopathic arthritis (Ophthalmology. 2019;126:415-424). ( 30803528 )
2019
19
Tocilizumab for refractory uveitis associated with juvenile idiopathic arthritis: A report of two cases. ( 30815892 )
2019
20
Safety and efficacy of dexamethasone implant along with phacoemulsification and intraocular lens implantation in children with juvenile idiopathic arthritis associated uveitis. ( 30574896 )
2019
21
Evaluation of controlled-release triamcinolone acetonide-loaded mPEG-PLGA nanoparticles in treating experimental autoimmune uveitis. ( 30641491 )
2019
22
Clinical and Functional Evaluation of Ocular Inflammatory Disease Using the Model of Experimental Autoimmune Uveitis. ( 30649775 )
2019
23
Controlled release of corticosteroid with biodegradable nanoparticles for treating experimental autoimmune uveitis. ( 30660629 )
2019
24
Disruption of Intestinal Homeostasis and Intestinal Microbiota During Experimental Autoimmune Uveitis. ( 30695094 )
2019
25
Microbiome and Autoimmune Uveitis. ( 30837991 )
2019
26
AS101 ameliorates experimental autoimmune uveitis by regulating Th1 and Th17 responses and inducing Treg cells. ( 30853312 )
2019
27
Implications of Birdshot-Like Uveitis on the Pathogenesis of Birdshot Chorioretinopathy. ( 30869756 )
2019
28
Implications of Birdshot-Like Uveitis on the Pathogenesis of Birdshot Chorioretinopathy-Reply. ( 30869757 )
2019
29
Long-term outcomes of cataract surgery in children with uveitis. ( 30900580 )
2019
30
Clinical profile of uveitis patients developing central serous chorioretinopathy: An experience at a tertiary eye care center in India. ( 30672479 )
2019
31
Diabetes Mellitus-Associated Uveitis: Clinical Features in a Chilean Series. ( 30811256 )
2019
32
Pre-eclampsia/Eclampsia as a Risk Factor of Noninfectious Uveitis Among Postdelivery Women. ( 30316670 )
2019
33
Swept-source optical coherence tomography angiography reveals vascular changes in intermediate uveitis. ( 30729711 )
2019
34
A Case of Uveitis in a Patient With Juvenile Myelomonocytic Leukemia Successfully Treated With Adalimumab. ( 30807392 )
2019
35
Acute hypertensive uveitis as the first presentation of multiple sclerosis. ( 30574934 )
2019
36
Clinical Manifestations, Prognosis And Vaccination Status Of Patients With Rubella Virus-Associated Uveitis. ( 30771336 )
2019
37
Tofacitinib for refractory uveitis and scleritis. ( 30582071 )
2019
38
Treatment of chronic non-infectious uveitis and scleritis. ( 30852832 )
2019
39
Prefoldin 5 and Anti-prefoldin 5 Antibodies as Biomarkers for Uveitis in Ankylosing Spondylitis. ( 30891043 )
2019
40
A Case of Tubulointerstitial Nephritis with Uveitis ( 30896673 )
2019
41
Reclassifying Idiopathic Uveitis: Lessons From a Tertiary Uveitis Center. ( 30352197 )
2019
42
Factors Affecting Relapse and Remission in Behçet's Uveitis Treated with Interferon Alpha2a. ( 30359208 )
2019
43
Management of presumed trematode induced granulomatous uveitis in pediatric patients. ( 30386949 )
2019
44
Relevance of erythrocyte sedimentation rate and C-reactive protein in patients with active uveitis. ( 30411142 )
2019
45
Uveitis: contrasting the approaches in Japan and the United States. ( 30460514 )
2019
46
Visual rehabilitation of patients with low vision in uveitis. ( 30574902 )
2019
47
Current and Emerging Pharmaceutical Therapies for Noninfectious Uveitis. ( 30585921 )
2019
48
Effect of Interferon alfa-2a Treatment on Adaptive and Innate Immune Systems in Patients With Behçet Disease Uveitis. ( 30601931 )
2019
49
UVEOGENE: An SNP database for investigations on genetic factors associated with uveitis and their relationship with other systemic autoimmune diseases. ( 30614601 )
2019
50
A novel application of B-ultrasonography at various head positions in the diagnosis of untypical uveitis-glaucoma-hyphema (UGH) syndrome: A case report. ( 30633162 )
2019

Variations for Uveitis

Expression for Uveitis

Search GEO for disease gene expression data for Uveitis.

Pathways for Uveitis

Pathways related to Uveitis according to GeneCards Suite gene sharing:

(show top 50) (show all 73)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.11 CCL2 CTLA4 HLA-B ICAM1 IFNA2 IFNG
2
Show member pathways
13.93 CAPN5 CCL2 CXCR3 IL10 IL17A IL1A
3
Show member pathways
13.75 CCL2 CXCR3 IFNA2 IFNG IL10 IL17A
4
Show member pathways
13.61 CCL2 ICAM1 IFNA2 IFNG IL10 IL17A
5
Show member pathways
13.51 CCL2 CXCR3 IL10 IL17A IL1A IL1R1
6
Show member pathways
13.38 CCL2 CXCR3 IL10 IL17A IL1A IL1R1
7
Show member pathways
13.38 CCL2 HLA-B ICAM1 IFNA2 IFNG IL10
8
Show member pathways
13.27 CCL2 IFNA2 IFNG IL10 NOD2 TGFB2
9
Show member pathways
13.04 CCL2 HLA-B ICAM1 IFNA2 IL1R1 TGFB2
10
Show member pathways
12.91 CTLA4 HLA-B ICAM1 IFNA2 IFNG IL10
11 12.87 IFNA2 IFNG IL2RA IL4 TGFB2
12
Show member pathways
12.69 IFNG IL10 IL2RA IL4 TNF
13
Show member pathways
12.68 CCL2 HLA-B ICAM1 IFNA2 IFNG IL1A
14
Show member pathways
12.65 CCL2 IFNG IL10 IL17A TNF
15 12.64 CCL2 CTLA4 IFNG IL10 IL17A IL2RA
16
Show member pathways
12.63 HLA-B ICAM1 IFNA2 IFNG IL4 TNF
17
Show member pathways
12.56 IFNG IL10 IL17A IL1A IL1R1 IL2RA
18
Show member pathways
12.54 CTLA4 IFNG IL10 IL17A IL1A IL4
19
Show member pathways
12.48 IFNA2 IFNG IL10 IL2RA IL4
20 12.48 HLA-B ICAM1 IL1R1 IL2RA TGFB2 TNF
21
Show member pathways
12.47 CAPN5 IL1A IL1R1 IL2RA
22
Show member pathways
12.43 CCL2 ICAM1 IFNG IL4 TNF
23
Show member pathways
12.43 CCL2 IFNG IL17A IL4 TNF
24
Show member pathways
12.38 IFNG IL10 IL1A IL4 TGFB2 TNF
25
Show member pathways
12.35 CCL2 IL1A IL1R1 NOD2
26 12.35 IFNA2 IFNG IL10 IL1A NOD2 TGFB2
27
Show member pathways
12.34 IFNG IL1A IL1R1 TNF
28
Show member pathways
12.27 IFNA2 IFNG IL1A TNF
29
Show member pathways
12.25 IFNG IL1R1 IL4 TNF
30 12.22 CCL2 ICAM1 IFNG IL1A IL1R1 TNF
31 12.17 IFNG IL1A IL1R1 TGFB2 TNF
32
Show member pathways
12.17 IFNG IL10 IL17A IL1R1 TGFB2 TNF
33
Show member pathways
12.17 HLA-B IFNA2 IFNG IL10 IL17A IL1A
34 12.15 CCL2 ICAM1 IFNG IL1A IL1R1 IL4
35 12.11 IFNA2 IFNG IL10 IL2RA IL4 TNF
36 12.11 CCL2 ICAM1 IL10 IL17A IL1A IL4
37
Show member pathways
12.08 CCL2 ICAM1 IFNG IL10 IL17A IL1A
38
Show member pathways
12.06 IFNG IL1R1 IL2RA IL4
39 12.05 CCL2 ICAM1 NOD2 TNF
40 12.05 CCL2 ICAM1 IL1A TGFB2 TNF
41 12.03 IL1A IL1R1 IL2RA IL4 TNF
42 12.02 IFNG IL10 IL1R1 TGFB2 TNF
43 11.96 IFNA2 IFNG IL10 IL2RA
44 11.9 ICAM1 IL1R1 TNF
45
Show member pathways
11.88 CTLA4 IFNG IL2RA IL4 TNF
46 11.87 IFNG TGFB2 TNF
47 11.86 IFNA2 IFNG IL10 TNF
48 11.83 ICAM1 IFNG IL4
49 11.8 IL10 IL1A TNF
50 11.8 CCL2 IFNG IL10 IL17A IL4 TGFB2

GO Terms for Uveitis

Cellular components related to Uveitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.9 CCL2 ICAM1 IFNA2 IFNG IL10 IL17A
2 cell surface GO:0009986 9.56 CAPN5 CXCR3 HLA-B ICAM1 IL1R1 IL2RA
3 external side of plasma membrane GO:0009897 9.17 CTLA4 CXCR3 ICAM1 IL17A IL1R1 IL2RA
4 extracellular region GO:0005576 10 CCL2 IFNA2 IFNG IL10 IL17A IL1A

Biological processes related to Uveitis according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.97 IFNA2 IFNG TGFB2 TNF
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.97 CCL2 ICAM1 NOD2 TNF
3 cell surface receptor signaling pathway GO:0007166 9.87 CCL2 CXCR3 IFNA2 IFNG IL1R1 IL2RA
4 inflammatory response GO:0006954 9.86 CCL2 CXCR3 IFNA2 IL10 IL17A IL1A
5 cellular response to interleukin-1 GO:0071347 9.85 CCL2 ICAM1 IL17A
6 B cell differentiation GO:0030183 9.84 IFNA2 IL10 IL4
7 cellular response to organic cyclic compound GO:0071407 9.83 CCL2 NOD2 TNF
8 interferon-gamma-mediated signaling pathway GO:0060333 9.83 HLA-B ICAM1 IFNG
9 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.83 IFNA2 IFNG IL4
10 regulation of inflammatory response GO:0050727 9.82 IL1R1 NOD2 TNF
11 regulation of signaling receptor activity GO:0010469 9.81 CCL2 IFNA2 IFNG IL10 IL17A IL1A
12 cellular response to lipopolysaccharide GO:0071222 9.8 CCL2 ICAM1 IL10 NOD2 TNF
13 interleukin-1-mediated signaling pathway GO:0070498 9.79 IL1A IL1R1 NOD2
14 extrinsic apoptotic signaling pathway GO:0097191 9.78 IFNG TGFB2 TNF
15 positive regulation of nitric oxide biosynthetic process GO:0045429 9.77 ICAM1 IFNG TNF
16 negative regulation of T cell proliferation GO:0042130 9.75 CTLA4 IL10 IL2RA
17 negative regulation of endothelial cell apoptotic process GO:2000352 9.74 ICAM1 IL10 IL4
18 positive regulation of cytokine secretion GO:0050715 9.69 IL10 IL1A TNF
19 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.68 CCL2 NOD2
20 humoral immune response GO:0006959 9.67 CCL2 IFNA2 IFNG TNF
21 positive regulation of osteoclast differentiation GO:0045672 9.65 IFNG IL17A TNF
22 cytokine-mediated signaling pathway GO:0019221 9.65 CCL2 ICAM1 IFNA2 IL10 IL17A IL1A
23 endothelial cell apoptotic process GO:0072577 9.64 IL10 TNF
24 positive regulation of MHC class II biosynthetic process GO:0045348 9.64 IL10 IL4
25 negative regulation of cytokine secretion involved in immune response GO:0002740 9.63 IL10 TNF
26 regulation of regulatory T cell differentiation GO:0045589 9.63 CTLA4 IFNG IL2RA
27 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.62 ICAM1 TNF
28 positive regulation of interleukin-23 production GO:0032747 9.61 IFNG IL17A
29 negative regulation of immune response GO:0050777 9.61 CTLA4 IL2RA TGFB2
30 regulation of isotype switching GO:0045191 9.59 IL10 IL4
31 type 2 immune response GO:0042092 9.58 IL10 IL4
32 negative regulation of alkaline phosphatase activity GO:0010693 9.56 TGFB2 TNF
33 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.55 IFNG TNF
34 receptor biosynthetic process GO:0032800 9.54 IL10 TNF
35 regulation of complement-dependent cytotoxicity GO:1903659 9.52 IL10 TGFB2
36 positive regulation of vitamin D biosynthetic process GO:0060557 9.49 IFNG TNF
37 immune response GO:0006955 9.4 CCL2 CTLA4 CXCR3 HLA-B IFNG IL10
38 apoptotic process GO:0006915 10.11 CXCR3 IFNA2 IFNG IL17A IL1A IL2RA

Molecular functions related to Uveitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.28 CCL2 IFNA2 IFNG IL10 IL17A IL1A

Sources for Uveitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....